酪酸梭菌二联活菌散联合复方胃蛋白酶颗粒治疗小儿功能性消化不良的临床研究

目的 探讨酪酸梭菌二联活菌散联合复方胃蛋白酶颗粒治疗小儿功能性消化不良的临床疗效。方法 回顾性分析2020年2月—2021年2月在郑州大学附属儿童医院诊治的104例功能性消化不良患儿的临床资料，根据就诊顺序分为对照组和治疗组，每组各52例。对照组口服复方胃蛋白酶颗粒，10 g/次，3次/d；治疗组在对照组基础上口服酪酸梭菌二联活菌散，500 mg/次，2次/d。两组患儿治疗2周。观察两组患儿临床疗效，比较治疗前后两组患儿FDDQL评分、临床症状评分、GOSS评分，血清胃肠激素和脑肠肽水平，胃电图指标。结果 经治疗，对照组和治疗组的临床有效率分别为84.62%、98.08%（P<0.05）。经治疗，两组FDDQL评分明显升高，而临床症状评分和GOSS评分明显下降（P<0.05），且治疗组患儿评分明显好于对照组（P<0.05）。经治疗，两组患儿血清胃动素（MTL）和神经肽Y（NPY）水平明显升高，而胃泌素（GAS）、生长抑素（SS）和血管活性肠肽（VIP）水平均明显下降（P<0.05），且治疗组患儿血清胃肠激素、脑肠肽水平明显好于对照组（P<0.05）。经治疗，两组患儿平均收缩波频率（MFC）、收缩波幅值（AC）均明显升高（P<0.05），且治疗组患儿胃电图指标水平明显高于对照组患儿（P<0.05）。结论 酪酸梭菌二联活菌散联合复方胃蛋白酶颗粒治疗小儿功能性消化不良可有效改善患儿临床症状，促进机体胃肠激素、脑肠肽分泌的改善，有利于胃电节律和生活质量的改善。

Clinical study on Combined Clostridium Butyricum and Bifidobacterium Powders, Live combined with Compound Saccharated Pepsin Granules in treatment of children with functional dyspepsia

Objective To investigate the clinical efficacy of Combined Clostridium Butyricum and Bifidobacterium Powders combined with Compound Saccharated Pepsin Granules in treatment of children with functional dyspepsia. Methods The clinical data of 104 children with functional dyspepsia diagnosed and treated in Children''s Hospital Affiliated to Zhengzhou University from February 2020 to February 2021 were divided into control and treatment groups according to visiting order, and each group had 52 cases. Patients in the control group were po administered with Compound Saccharated Pepsin Granules, 10 g/time, three times daily. Patients in the treatment group were po administered with Combined Clostridium Butyricum and Bifidobacterium Powders, Live, 500 mg/time, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical evaluation was evaluated, the FDDQL scores, clinical symptom scores and GOSS scores, serum gastrointestinal hormone and brain-gut peptide levels, and the level of electrogastrogram indexes in two groups before and after treatment were compared. Results After treatment, the clinical effective rates of the control group and the treatment group were 84.62% and 98.08% respectively (P<0.05). After treatment, the FDDQL score were significantly increased, while the clinical symptom score and GOSS score were significantly decreased in two groups (P<0.05), and the scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the levels of serum MTL and NPY were significantly increased, while the levels of GAS, SS and VIP were significantly decreased in two groups (P<0.05), and the levels of serum gastrointestinal hormone and brain-gut peptide in the treatment group were significantly better than those in the control group (P<0.05). After treatment, MFC and AC were significantly increased in two groups, and the level of electrogastrogram in the treatment group was significantly higher than that in the control group (P<0.05). Conclusion Combined Clostridium Butyricum and Bifidobacterium Powders, Live combined with Compound Saccharated Pepsin Granules in treatment of children with functional dyspepsia can effectively improve the clinical symptoms of children, promote the secretion of gastrointestinal hormones and brain-gut peptides, and be beneficial to the improvement of gastroelectric rhythm and quality of life.